- Report
- October 2023
- 157 Pages
Global
From €5244EUR$5,500USD£4,495GBP
- Report
- March 2024
- 181 Pages
Global
From €3217EUR$3,374USD£2,757GBP
€3575EUR$3,749USD£3,064GBP
- Report
- February 2024
- 125 Pages
Global
From €5673EUR$5,950USD£4,863GBP
- Report
- December 2023
- 111 Pages
Global
From €5673EUR$5,950USD£4,863GBP
- Report
- December 2023
- 200 Pages
Global
From €4767EUR$5,000USD£4,086GBP
- Report
- December 2023
- 200 Pages
Global
From €4767EUR$5,000USD£4,086GBP
- Report
- January 2024
- 150 Pages
Global
From €4624EUR$4,850USD£3,964GBP
- Report
- March 2024
- 148 Pages
Global
From €3718EUR$3,899USD£3,186GBP
- Report
- May 2024
- 184 Pages
Global
From €4720EUR$4,950USD£4,045GBP
- Report
- September 2023
- 180 Pages
Global
From €5673EUR$5,950USD£4,863GBP
- Report
- November 2023
- 145 Pages
Global
From €2383EUR$2,499USD£2,042GBP
- Report
- February 2024
- 120 Pages
Global
From €4529EUR$4,750USD£3,882GBP
- Report
- August 2023
- 118 Pages
Global
From €7151EUR$7,500USD£6,129GBP
- Report
- October 2023
- 185 Pages
Global
From €4672EUR$4,900USD£4,004GBP
- Report
- November 2023
- 140 Pages
Global
From €4243EUR$4,450USD£3,637GBP
- Report
- November 2023
- 165 Pages
Global
From €2384EUR$2,500USD£2,043GBP
- Report
- February 2024
- 90 Pages
United States
From €4529EUR$4,750USD£3,882GBP
- Report
- September 2021
- 90 Pages
Global
From €858EUR$900USD£736GBP
- Report
- October 2021
- 154 Pages
Global
From €5292EUR$5,550USD£4,536GBP
- Report
- October 2022
- 216 Pages
Middle East
From €2002EUR$2,100USD£1,716GBP
€2860EUR$3,000USD£2,452GBP
Low Molecular Weight Heparin (LMWH) is a class of anticoagulant drugs used to prevent and treat thromboembolic disorders, such as deep vein thrombosis and pulmonary embolism. LMWH is a form of heparin, a naturally occurring anticoagulant, that has been modified to reduce its molecular weight and increase its bioavailability. LMWH is administered subcutaneously and has a longer half-life than unfractionated heparin, allowing for once-daily dosing. LMWH is also associated with fewer side effects than unfractionated heparin, making it a preferred treatment for cardiovascular diseases.
The LMWH market is a growing segment of the cardiovascular drugs market, with a wide range of products available. LMWH is used in a variety of clinical settings, including the prevention and treatment of thromboembolic disorders, the prevention of post-operative thrombosis, and the treatment of unstable angina and acute coronary syndrome.
Some of the major companies in the LMWH market include Sanofi, Pfizer, Bayer, and Bristol-Myers Squibb. Show Less Read more